Volume Down, Margins Pinched—But the Pipeline Holds
Revenue beat expectations despite a 6–7% volume decline, but profit fell 5% YoY as margins compressed. The quarter tests whether premium-mix gains are sustainable or a temporary offset.
₹686.3 Cr
+7.6% YoY, +12.2% QoQ
₹56.2 Cr
-5% YoY, +28% QoQ
33.7%
-80 bps YoY
-6 to -7%
Offset by premium mix
Insecticides (India) reported a Q2 that looked better on the surface than underneath. Revenue of ₹686.3 crore met the premium-product narrative—up 7.6% despite a 6–7% volume drop—but the profit line told a different story. Net profit slid 5% to ₹56.2 crore, and gross margins compressed 80 basis points to 33.7%. This was not a quarter where premiumization delivered margin expansion; it was a quarter where premiumization prevented a sharper profit decline.
The quarter in three numbers
Start with volume. Management disclosed a 6–7% volume decline in Q2, driven by weak farmer sentiment post-monsoon disruption (El Niño impact). In prior commentary, management had guided for stabilization; instead, the trend deteriorated. To compensate, the company shifted its sales mix toward premium and specialty products—Maharatna, Focused Maharatna, and the nascent Kaeros brand—achieving ~4–5% value growth. That mix shift was real: premium products now represent 60%+ of the sales portfolio, with a 70% target over 2–3 years.
But premium mix alone does not offset 6–7% volume at current gross-margin structures. Gross margin fell to 33.7% from 34.5% a year ago, even as the company emphasized cost discipline and premiumization. EBITDA margin held at 13.5% (₹92.4 crore), but PAT declined to ₹56.2 crore from ₹59.2 crore, a 5% year-over-year drop. The profitability compression is real and unambiguous.
Claims graded against the numbers
8% revenue growth in Q2
7.6% YoY growth; ₹686.3 Cr vs ₹637 Cr prior year
Supported (close call)
Premiumization and value growth offsetting volume decline
True on revenue (+7.6%); false on profit (PAT -5%) and margins (-80 bps)
Overstated on profitability impact
Working capital improving via operational focus
WC days 158 vs 151 (+7 days); inventory ₹814 Cr vs ₹744 Cr (+₹70 Cr)
Contradicted; deteriorated ₹34 Cr net
Margins consistent, profitability intact
Gross margin -80 bps, EBITDA flat, PAT -5%
Overstated; near-term compression evident
What changed on this call
Management raised or firmed three material pieces of guidance. Kaeros, the company's premium agrochemical brand, is scaling faster than initial targets. Originally guided at 50–60% CAGR, the company now explicitly targets ₹125–200 crore brand turnover by fiscal-year-end or FY28, with a longer-term path to double that. The brand has already hit ₹114 crore in H1 sales, a 50%+ CAGR pace. International business received its first quantified target: 40–50% CAGR growth toward ₹500 crore over 5 years, starting from a ~5% base. This is new specificity and a material shift in strategy away from domestic generics. Premium product mix target was raised to 70% over 2–3 years, from the current 60%+.
Conversely, capex timelines slipped. Dahej DCS plant, expected in H1, is now targeted for Q3 completion (by December 2026). Sotanala formulation unit is now targeted for April Q4, with technical manufacturing to follow in FY28. And volume remained unresolved—management conceded flat to slightly negative FY27 full-year volume instead of the stabilization previously implied. These are modest reversals, but they reveal execution pressure and an inability to arrest the volume decline near-term.
Kaeros 50%+ CAGR on track; ₹114 Cr H1 run-rate; 800k+ distributor network proven
Premium product mix now 60%+; 70% target over 2–3 years; demand-driven
International strategy newly quantified (₹500 Cr over 5Y, 40–50% CAGR); 15+ AIs filed
Capex (Dahej, Sotanala) positions for CDMO and cost efficiency recovery
Volume declined 6–7% in Q2; management concedes flat/negative FY27 full year
Gross margin down 80 bps despite premiumization narrative; PAT down 5% despite revenue +7.6%
Working capital deteriorated ₹34 Cr; inventory up ₹70 Cr; days up 7 despite 'strategic holding' claim
Capex slipped (Dahej Q3 vs H1, Sotanala Q4 vs H2); execution risk evident
Margin compression sustained
MediumGross margin down 80 bps despite premiumization. If volume decline persists and mix shift slows, margin could compress further. Industry consolidation and pricing pressure from larger players limit near-term recovery.
Volume stabilization delayed into FY28
Medium6–7% decline in Q2; management now concedes flat/negative FY27. If farmer sentiment remains weak or monsoon impact extends, stabilization could slip further. Near-term growth headwind.
Working capital deterioration continues
MediumWC days up 7 to 158, inventory up ₹70 Cr, net WC up ₹34 Cr. If trend persists, cash generation is stressed, constraining capex or dividends. Seasonal normalization expected post-Diwali, but trend bears watching.
Capex execution delays cascade
MediumDahej slipped from H1 to Q3; Sotanala from H2 to Q4. Further delays could defer capex normalization and CDMO revenue ramp. Interest capitalization and working capital cycles prolonged.
International business early-stage execution risk
Medium₹500 Cr over 5Y target is ambitious from a ~5% base. Registrations, CDMO deals, partner relationships nascent. Long cycle (1–2Y per registration). Regulatory complexity and China competition pose risks.
Macro volatility (monsoon, commodity prices)
Low-MediumQ2 hit by El Niño; farmer profitability stressed. Crude/sea freight volatility passes through. Input cost inflation could compress margins further if pricing power is limited.
The street's view
Institutional ownership is flat and defensive. FII holdings slid marginally to 4.40% from 4.50% a quarter ago (−10 basis points), and DII holdings are essentially unchanged at 9.26%. Promoter ownership remains stable at 72.30%. No evidence of bulk buying or insider accumulation near current levels. The ownership profile suggests the market is neither excited nor panicked—a 'show me' stance. This matches the fundamental picture: management has a credible long-term pipeline, but near-term earnings are soft, and visibility on margin recovery is limited. Institutions are waiting for evidence that the premium-mix thesis translates to bottom-line strength before stepping in.
1 · Q3 volume and margin trajectory
Does volume stabilize into H2 as management projects, or does the 6–7% decline persist? If volume remains negative and mix shift slows, gross margin could compress further. Watch for management commentary on farmer sentiment and pre-Diwali sales trends in next earnings call.
2 · Dahej and Sotanala capex completion
Both plants are on the critical path for cost normalization and CDMO revenue ramp. Q3 update on Dahej progress (currently expected December 2026) and Q4 formulation unit startup (April 2027) are key execution milestones. Delays extend the margin recovery timeline.
3 · Working capital normalization
Current WC days of 158 are elevated. Management cited 'strategic inventory holding' pre-Diwali; normalization back toward 150–151 days post-festival would be a positive signal on cash generation and operational discipline. H2 working capital update will be scrutinized.
4 · Kaeros margin structure clarity
Kaeros H1 sales of ₹114 Cr are strong, but the gross-margin contribution (vs. core business) is not yet clear. As Kaeros scales toward ₹200 Cr, understanding its margin profile will be essential to assess whether premiumization thesis holds at consolidated level.
Insecticides (India) is executing on a credible long-term transformation: Kaeros is on a 50%+ CAGR path, international exposure is being built systematically, and a 30+ molecule pipeline is advancing. But the near-term quarter reveals a softer baseline than management's prior commentary implied. Volume is down, margins are compressing, working capital is deteriorating, and capex is slipping. The central question is whether premium mix and Kaeros scale can stabilize profitability before the broader cyclical headwind (farmer weakness, commodity volatility, weather disruption) extends further.
Q2 was not a disaster—the premium mix prevented it from being one. But it was not a vindication of the premiumization thesis either. Management is holding the line on long-term guidance (Kaeros ₹200 Cr, international ₹500 Cr), and the analyst community is watching execution closely. A steady operational quarter is in order to rebuild credibility on margins.
The single number to track from here: Gross margin. If Q3 stabilizes or expands from 33.7%, the premium-mix thesis regains credibility. If it compresses further, the structural headwinds (volume, commodity, competition) are winning, and near-term fair value is lower.
Insecticides India Q2 FY27: consolidated PAT falls 5% YoY to ₹56 Cr as margins compress
PAT -4.97% YoY · revenue +7.62% · margins compressing
₹686.31 Cr
+7.62% YoY
₹56.17 Cr
-4.97% YoY
8.19%
-1pp YoY
₹19.3
Insecticides (India)'s consolidated (primary) Q2 FY27 print: revenue ₹686.31 Cr, up 7.62% YoY from ₹637.70 Cr, but PAT fell 4.97% YoY to ₹56.17 Cr from ₹59.11 Cr a year ago — profit declined even as the topline grew, the signature of margin compression rather than a demand problem. No exceptional or one-off items are disclosed on the face of either statement, so this is a straight reported-number read with no adjustment required. Standalone PAT of ₹50.58 Cr runs roughly 11% below the consolidated figure, with subsidiaries/the jointly controlled entity contributing the gap — a divergence worth flagging since readers may encounter either number elsewhere.
Q2 FY-2027 vs prior quarters
Sequentially the picture looks very different: revenue is up 12.23% and PAT up 28.02% versus Q1 FY27's monsoon-depressed base (revenue ₹611.52 Cr, PAT ₹43.87 Cr, NPM 7.11%, OPM 11.06%) — but per YoY-primacy this QoQ jump is a seasonal/base-effect rebound, not the headline story. Net margin compressed to ~8.20% of total income from 9.23% a year ago, and operating margin eased to roughly 13.5% from ~14.0% YoY, even as EBITDA grew in absolute ₹ Cr terms; the squeeze traces to cost of materials consumed and purchase of stock-in-trade rising faster than revenue, per the expense break-up in the filing.
The stock went into the print at ₹547.45, down 6.4% over the past month of trading.
For context: PAT has now risen for 3 consecutive quarters.
What the summary numbers don't show
Basic EPS ₹19.30 consolidated (₹17.38 standalone) vs ₹20.31 YoY and ₹15.08 QoQ
No explicit FY27 revenue or PAT guidance restated. MD deferred full-year targets pending H2 review, citing weak Q1 from monsoon. Granuvia & Spinoace targeted at ₹30–35 Cr combined gross FY27. KAEROS targeting 100% CAGR initially, then 50–60%. Capex to normalize at ₹30–40 Cr maintenance post-Sotanala.
Management offered no formal FY27 revenue or PAT guidance on the Q1 concall, deferring full-year targets pending an H2 review after a rain-hit Q1 — so there is no numeric bar to grade this print against (vsGuidance: unknown, not beat/miss). No management press release was available for this result, so there is no company quote to cross-check against the numbers this quarter. A pre-result preview (Univest, Sep 18, 2026) flagged margin trajectory and the Granuvia ramp as the quarter's swing factors but carried no numeric consensus estimate, so vsStreet is also unknown. The filing does not break out Granuvia/Spinoace or KAEROS revenue, so the ₹30–35 Cr combined FY27 target and KAEROS' CAGR goals cited on the prior concall cannot be checked this quarter. Alongside the results, the board declared an interim dividend of ₹5/share (record date Nov 12, 2026, payable from Nov 17, 2026) and approved a new Additional Independent Director and a new AVP for Tech Services Projects & Manufacturing Excellence — governance actions unrelated to the quarter's numbers.
W1
Whether OPM holds near the ~13.5% Q2 level or slips further in H2 — flagged as the key swing factor in the pre-result preview
W2
Granuvia & Spinoace combined gross revenue vs the ₹30–35 Cr FY27 target cited on the Q1 concall — no product-level split disclosed this quarter
W3
H2 capex run-rate against the ₹30–40 Cr/quarter maintenance guidance post-Sotanala — H1 consolidated capex was ₹55.76 Cr (~₹28 Cr/quarter)
Consolidated PAT (₹56.17 Cr) exceeds standalone (₹50.58 Cr) by ~11% via subsidiary/JV contribution (JV share ₹0.23 Cr); other income is negative in both statements (-₹0.88 Cr standalone, -₹0.84 Cr consolidated); no exceptional items disclosed on the face of the P&L.
Strong pipeline, soft quarter; margin compression raises near-term questions
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Guided 50–60% Kaeros CAGR; now raising to 50%+ with ₹200 Cr target. New intl guidance (₹500 Cr, 5Y) adds specificity. But Q2 missed on margin expansion and volume stabilization expectations.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Management is executing a credible long-term transformation—Kaeros 50%+ CAGR, international CDMO expansion, 30+ molecule pipeline—but Q2 delivery is soft and near-term catalysts delayed. Revenue growth is 7.6%, PAT down 5%, gross margins compressing 80 bps YoY, and working capital has deteriorated ₹34 Cr. Execution risk on capex (Dahej, Sotanala) and margin pressure from weather/commodity volatility remain near-term headwinds.
₹686.3 Cr
Revenue · +7.6% YoY₹56.2 Cr
Reported PAT · −5% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
8% revenue growth in Q2
MET7.6% YoY growth; ₹686.3 Cr vs ₹637 Cr prior year
Gross margin 33.7% in Q2
MET33.7% reported; compressing from 34.5% prior year
EBITDA 13.5%, PAT ₹56 Cr in Q2
METOPM 13.5%, PAT ₹56.2 Cr match exactly
Volume growth negative, value growth driving performance
METAdmitted 6–7% volume decline; revenue +7.6% means value/mix raised by ~14–15%
Working capital improving via operational focus
MISSWC days 158 (H1 FY27) vs 151 (H1 FY26); inventory ₹814 Cr vs ₹744 Cr; net WC ₹1,000 Cr vs ₹966 Cr — deteriorating
PAT margins on track, profitability intact
OVERSTATEDPAT ₹56.2 Cr vs ₹59.2 Cr prior year = -5% YoY; NPM 8.2% is stable but absolute PAT down
Earnings quality
What changed since the last call
Kaeros guidance firmed
UpgradePrior: '50–60% CAGR.' Now: ₹125 Cr brand target, ₹200 Cr gross FY27/28, 50%+ CAGR. Standalone Kaeros could reach ₹200 Cr by year-end, then double.
International business newly quantified
NewFirst explicit targets: 40–50% CAGR, ₹500 Cr total over 5 years from intl markets. Prior call had no international revenue guidance.
Premium product mix target raised
UpgradeNew: 70% premium product mix target. Prior call silent on this specific ratio.
Volume trend remains negative
DowngradeManagement admitted 6–7% volume decline in Q2 and expectations for flat/slightly negative FY27 volume. Prior call hinted at stabilization.
Capex timeline slipped slightly
DowngradeDahej was 'first half of year'; now Q3. Sotanala was 'next fiscal'; now Q4 formulation launch implied. Minor slip but shows execution pressure.
The Q&A
Analysts pressed hard on volume, international progress, capex delays, margin outlook. Rajesh held firm, providing detail (15+ AIs filed, 28 molecules in domestic portfolio, 800k+ Kaeros distributors appointed). No evidence of evasion, but acknowledged headwinds without conceding near-term margin recovery.
Volume and segment growth — Bharat Gupta, Fair Value Capital
AnsweredNegative volume in quarter (6–7% drop). Value growth 4–5% from premium mix. Maharatna seen improvement; focus on premium products, not volume chase.
Kaeros scaling — Bharat Gupta, Fair Value Capital
AnsweredKaeros doing very well, ₹75 Cr brand in FY26, ₹114 Cr H1 FY27 sales. Target ₹125–200 Cr gross by year-end; can double next year. 50%+ CAGR trajectory.
Product pipeline and 9(3) launches — Bharat Gupta, Fair Value Capital
Partial30 molecules in development; 12 already filed. Nissan new product first, then 9(3) mixtures. Oil product delayed pending CIB clearance; timing uncertain but expected next season.
Dahej and Sotanala capex status — Praneeth, SJ Investments
AnsweredDahej now expected Q3 completion (was H1). Plant partially in production; full swing after December restart. Sotanala formulation target April; technical manufacturing next fiscal.
Volume outlook for full year — Praneeth, SJ Investments
AnsweredNot a growth year for volume; ending roughly flat. Very confident value growth will offset; H2 improvements expected.
Margin trajectory and premiumization — Praneeth, SJ Investments
PartialAlready at 33–34% level. Target to match industry best step-by-step. ~1% growth possible on average; some years may jump 2–3%.
Team expansion and cost inflation — Praneeth, SJ Investments
AnsweredCurrent on-roll team ~750 (parity with best in industry). H2 additions limited to third-party roles. No major headcount plans this fiscal.
Distributor and retailer tracking systems — Praneeth, SJ Investments
AnsweredHave DMS but informal tracking too (QR system, Beetroot platform in Kaeros). Market visibility ~15–20% currently; aiming 60–70% with scheme rollouts and enhanced participation.
International and CDMO strategy — Yash, Grit Securities
AnsweredStarted with brand/white label; now pivoting to technicals. Registrations in Americas, Europe, ASEAN. 15 AIs filed; targeting traction in technicals market. CDMO model emerging with partners (Japanese JVs, developing relationships).
CDMO business model clarity — Yash, Grit Securities
PartialCDMO = contracted business where company manufactures molecule exclusively/semi-exclusively for partner (vs. China models). Developing parallel supplier relationships. Sotanala and Dahej plants positioned to qualify for CDMO contracts.
OAT Agrio product development — Santosh Shetty, DD Capital
PartialTarget 2027 launch; application filed, Schedule inclusion pending. If approved, launch possible within ~1 year. Once first product launches, start second; strong pipeline of 3–5 launches expected. Spinoace/Granuvia new technologies with lukewarm market response; recovery expected in H2 rabi crop.
R&D investment and molecule portfolio — Santosh Shetty, DD Capital
AnsweredInnovation/R&D focused. 4 R&D centers across India; spend ~₹12–20 Cr booked as marketing (not classified as R&D for tax purposes). 35 molecules registered (formulations + technicals); 12+ filed; expect 30+ total in next 2–3 years. R&D = performance, not show.
Kaeros 200 Cr potential and standalone runway — Rajiv Jain, Arcane Investments
AnsweredKaeros ~₹75 Cr gross in FY26; ₹100+ Cr sales in H1 FY27. Target ₹125 Cr brand in FY27, ₹200 Cr gross by fiscal-end or next year. Kaeros stand-alone could touch ₹200 Cr, then double. 50%+ CAGR expected.
Premium product mix and margin impact — Rajiv Jain, Arcane Investments
AnsweredPremium products currently ~60%+ of mix. Target 70% over 2–3 years. Strategy formed years ago when premium contributed 50%. Growth coming from Kaeros, Maharatna volumes. No sales push needed; farmer demand strong.
Returns and PAT loss provisions — Praneeth, SJ Investments
PartialQ2 and H1 numbers shared; returns high in H1 but normal going forward. Q3 will be positive recovery; H2 should show improvement. Loss to PAT margin is ~crore level in Q2; H2 expected better, recovery visible.
Guidance
Kaeros ₹200 Cr gross turnover by FY27/28
HighCurrently ₹114 Cr H1; targeting ₹125–200 Cr by year-end or next fiscal. Standalone possible. 50%+ CAGR.
International ₹500 Cr target over 5 years, 40–50% CAGR
MediumCurrently ~5% of revenue; 15+ AIs in development; registrations in-progress. Long cycle time; execution risk high.
FY27 full-year volume flat, value growth positive
MediumQ2 saw -6–7% volume decline; expecting stabilization in H2. Value mix shift to continue offsetting volume.
Gross margin improvement ~1–3% annually
LowCurrently 33.7% (Q2); down 80 bps YoY. Premiumization strategy in place, but near-term compression evident. Target to step-by-step improve toward industry best.
EBITDA margin 12–14% range
MediumQ2 at 13.5%; H1 at 12.3%. Mix of Kaeros (high-margin nascent) and core (margin-compressed) businesses.
PAT margin stabilization post-Q2 weakness
MediumH1 PAT ~₹100 Cr combined. Management notes 'recovery visible in H2' but cannot guarantee near-term margin expansion.
Dahej DCS plant full commission by Q3 FY27 (Dec 2026)
Medium80% capitalized; expected ₹30–40 Cr total. Maintenance capex to normalize post-completion.
Sotanala formulation unit startup Q4; technical manufacturing next fiscal
MediumFormulation April target (post-Diwali shutdown), technical manufacturing to start full next fiscal.
Risks the call surfaced
Margin compression sustained
MediumGross margin down 80 bps YoY to 33.7%. Premiumization narrative not translating to expansion. If volume decline persists and mix shift slows, margin could compress further. Industry consolidation may pressure pricing.
Volume stabilization delayed
MediumQ2 saw 6–7% volume decline. Management confident in value offset, but absolute volume headwind persists. If farmer sentiment remains weak or monsoon impact extends, stabilization could slip into FY28.
Working capital deterioration
MediumWC days increased to 158 from 151. Inventory up ₹70 Cr (₹744→₹814 Cr), debtors up ₹76 Cr (₹643→₹719 Cr). Creditors up but not in line. If this trend continues, cash generation could be stressed, constraining capex or dividends.
Capex execution delays
MediumDahej expected Q3 (was H1); Sotanala formulation April (was H2). Minor slips, but if further delays occur, capex normalization and CDMO revenue ramp could slip. Interest capitalization and working capital cycles prolonged.
International business early-stage execution risk
MediumInternational target ₹500 Cr over 5Y at 40–50% CAGR is ambitious. Currently ~5% of revenue. Registrations, CDMO deals, partner relationships are all nascent. Long cycle time (1–2Y per registration), regulatory complexity, and competition from China pose risks.
Management
Score 7/10. Clear, transparent, and granular. Rajesh Aggarwal provides detailed answers on product pipeline, capex, strategy. Acknowledges headwinds (monsoon, El Niño, supply chain) without deflection. Some answers hedged (e.g., international timelines, margin expansion pace), but no evident NDA shields or non-answers. Mixed. Kaeros scaling on track; ₹114 Cr H1 run-rate validates 50%+ CAGR path. But core business volume negative, margins compressing, capex timelines slipped slightly. Working capital management unaddressed despite deterioration. Track record shows execution but not flawless pace.
1 · Q3 FY27 (Dec 2026)
Dahej DCS plant full commissioning; capex normalization begins
2 · Q4 FY27 (Mar 2027)
Sotanala formulation unit startup; CDMO formulation launches
3 · FY28 (Apr–Jun 2027)
Kaeros network fully established; 60 products live; southern markets rollout
Execution risk on capex (Dahej, Sotanala) and margin pressure from weather/commodity volatility remain near-term headwinds.